KRAS and Miyoshi myopathy: Concerning neoantigens and MM, several oncogenic driver mutations have been documented, affecting signaling pathways mediated by MEK/ERK, KRAS, NRAS, BRAF, and NF-κB, and also affecting genes involved in epigenetic regulation, such as HIST1H1E, KMT2C, and CREBBP [1,32].